Supply Chain
Alvotech Moves Biosimilar Drug-Substance Production to Syracuse Under a LOTTE Biologics Deal
The New York plant has 40,000 liters of bioreactor capacity and cleared an FDA inspection with no observations. Financial terms were not disclosed.
PR
By Priya Raghavan
Oct 6, 2026 · 2 min read
Alvotech and LOTTE Biologics announced a long-term manufacturing agreement after Tuesday's close under which LOTTE will produce drug substance for several of Alvotech's antibody biosimilars at its plant in Syracuse, New York, for global distribution. No financial terms were disclosed.
Discussion (0)
Sign in to join the discussion.
Loading comments…
PR
Priya Raghavan
Corporate Insider Inc.
Priya Raghavan writes for Corporate Insider Inc.